pathology+of+breast+carcinoma+fsm.ac.fj
TRANSCRIPT
![Page 1: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/1.jpg)
““Strength does not come from Strength does not come from winning. Struggles & Hardship winning. Struggles & Hardship develop your strength. When you go develop your strength. When you go through hardship and decide not to through hardship and decide not to surrender, that is strength”surrender, that is strength”
Arnold SchwarzeneggerArnold Schwarzenegger Bodybuilder and ActorBodybuilder and Actor
![Page 2: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/2.jpg)
Pathology of Breast Pathology of Breast CancerCancer
Dr. Venkatesh M. ShashidharDr. Venkatesh M. ShashidharSenior Lecturer in PathologySenior Lecturer in PathologyFiji School of MedicineFiji School of Medicine
![Page 3: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/3.jpg)
IntroductionIntroduction
Modified sweat glands.Modified sweat glands. Lobes and lobules of gland Lobes and lobules of gland in fat tissue stroma.in fat tissue stroma. Ducts emerge from acini of glandsDucts emerge from acini of glands Smaller ducts join to form Smaller ducts join to form
lactiferous ductslactiferous ducts Lactiferous ducts merge just Lactiferous ducts merge just
beneath the nipple to form a beneath the nipple to form a lactiferous sinus.lactiferous sinus.
Then individually open on nipple Then individually open on nipple
![Page 4: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/4.jpg)
Normal BreastNormal Breast
![Page 5: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/5.jpg)
Myoepithelial Cells (ipx)Myoepithelial Cells (ipx)
![Page 6: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/6.jpg)
DisordersDisorders CongenitalCongenital
Aplasia – turners, Juvenile hypertrophyAplasia – turners, Juvenile hypertrophy InflammatoryInflammatory
Infections acute/chronic – Trauma Fat necrosisInfections acute/chronic – Trauma Fat necrosis Duct ectasia discharge, sinusDuct ectasia discharge, sinus Fibrocystic disease – common – painful lumpsFibrocystic disease – common – painful lumps
NeoplasticNeoplastic Benign - FibroadenomaBenign - Fibroadenoma Malignant – Ca Malignant – Ca
![Page 7: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/7.jpg)
Fibrocystic DiseaseFibrocystic Disease
Fibroadenosis, Fibrocystic change, etc.Fibroadenosis, Fibrocystic change, etc. Commonest lump, 10-50% womenCommonest lump, 10-50% women ? Hormonal? Hormonal Periodic discomfort – pain.Periodic discomfort – pain. Eipethilial hyperplasia – premalignantEipethilial hyperplasia – premalignant Irregular palpable lumps – mimic ca.Irregular palpable lumps – mimic ca.
Adenosis – hyperplasia - cysts – papillomatosis – Adenosis – hyperplasia - cysts – papillomatosis – metaplasia – fibrosis.metaplasia – fibrosis.
![Page 8: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/8.jpg)
Benign Neoplasms:Benign Neoplasms:
Fibroadenoma Fibroadenoma Duct PapillomaDuct PapillomaAdenomaAdenomaConnective tissue tumorsConnective tissue tumors
Features (Fibroadenoma)Features (Fibroadenoma)Young age 3Young age 3rdrd decade. decade. Single, rounded, mobile, painless lumps. Single, rounded, mobile, painless lumps. No scarring or calcification.No scarring or calcification. Slit like glands in Fibrous stromaSlit like glands in Fibrous stroma
![Page 9: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/9.jpg)
Breast Carcinoma Breast Carcinoma
20% of all cancers in 20% of all cancers in womenwomen
Commonest cause of death - Commonest cause of death - 35-55y35-55y
In UK 1 in 10-12 chancesIn UK 1 in 10-12 chances 1 in 8 women in US1 in 8 women in US Less incidence in AsiaLess incidence in Asia Majority of cancers arise in Majority of cancers arise in
the ducts.the ducts. Very rare before age 25Very rare before age 25
![Page 10: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/10.jpg)
Risk Factors:Risk Factors:
Female sex..!, Age, Obesity, high fat diet Female sex..!, Age, Obesity, high fat diet Maternal relative with breast cancer. Maternal relative with breast cancer. Longer reproductive span. Longer reproductive span. Nulliparity, Oral contraceptivesNulliparity, Oral contraceptives Later age at first pregnancy. Later age at first pregnancy. Atypical epithelial hyperplasia. Atypical epithelial hyperplasia. Previous breast cancer/Endometrial Ca. Previous breast cancer/Endometrial Ca. Geographic factors - countryGeographic factors - country BRCA1 and BRCA2BRCA1 and BRCA2 genes genes
![Page 11: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/11.jpg)
Etiology of Breast Carcinoma:Etiology of Breast Carcinoma:
![Page 12: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/12.jpg)
Clinical Features:Clinical Features:
Physiologic vs Pathologic changesPhysiologic vs Pathologic changes Lump / lumpsLump / lumps Lumps are much more common than CaLumps are much more common than Ca Characters of Characters of lumplump* and * and ageage** Discharge in many conditions.Discharge in many conditions. Hard, soft, inflammationHard, soft, inflammation Skin fixation / Skin fixation / SkinSkin retractionretraction * *
![Page 13: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/13.jpg)
Diagnosis:Diagnosis:
MammorgraphyMammorgraphy UltrasoundUltrasound Fine Needle Aspiration BiopsyFine Needle Aspiration Biopsy Core BiopsyCore Biopsy Excision BiopsyExcision Biopsy Frozen sectionFrozen section Immunoperoxidase,Immunoperoxidase, Molecular techniques – Gene detection.Molecular techniques – Gene detection.
![Page 14: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/14.jpg)
Histological TypesHistological TypesHistologic Type Freq. (UK)
Infiltrating Duct Ca 63.6 (75)
Lobular Carcinoma 5.9 (10)
Infiltrating Ductal & Lobular Ca 1.6
Medullary Carcinoma 2.8 (3)
Mucinous (colloid) Carcinoma 2.1 (3)
Comedocarcinoma 1.4
Carcinoma-In-Situ 5%
![Page 15: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/15.jpg)
Breast Carcinoma Breast Carcinoma
![Page 16: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/16.jpg)
Breast Carcinoma Breast Carcinoma
![Page 17: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/17.jpg)
Breast Carcinoma - SchirrousBreast Carcinoma - Schirrous
![Page 18: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/18.jpg)
Infiltrating Duct Carcinoma: small hardInfiltrating Duct Carcinoma: small hard
![Page 19: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/19.jpg)
Medullary Carcinoma: Large softMedullary Carcinoma: Large soft
![Page 20: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/20.jpg)
Infiltrating Duct CarcinomaInfiltrating Duct Carcinoma
![Page 21: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/21.jpg)
Infiltrating Duct CarcinomaInfiltrating Duct Carcinoma
![Page 22: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/22.jpg)
Medullary Carcinoma: Inflammation.Medullary Carcinoma: Inflammation.
![Page 23: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/23.jpg)
Infiltrating Duct Carcinoma: FibrosisInfiltrating Duct Carcinoma: Fibrosis
![Page 24: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/24.jpg)
Schirrous CarcinomaSchirrous Carcinoma
![Page 25: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/25.jpg)
Medullary CarcinomaMedullary CarcinomaSoft, inflammatory cellsSoft, inflammatory cells
![Page 26: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/26.jpg)
Intraductal in-situ CarcinomaIntraductal in-situ Carcinoma
![Page 27: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/27.jpg)
Lobular CarcinomaLobular Carcinoma
![Page 28: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/28.jpg)
Intraduct Carcinoma-in-situIntraduct Carcinoma-in-situ
![Page 29: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/29.jpg)
Intraduct CarcinomaIntraduct Carcinoma
![Page 30: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/30.jpg)
Lymphatic spread – Peu-de Orange..Lymphatic spread – Peu-de Orange..
![Page 31: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/31.jpg)
Spread of Breast Spread of Breast Carcinoma:Carcinoma:
![Page 32: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/32.jpg)
Pagets DiseasePagets Disease
![Page 33: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/33.jpg)
Pagets Disease (Epidermal invasion)Pagets Disease (Epidermal invasion)
![Page 34: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/34.jpg)
Estrogen Receptor & Prognosis:Estrogen Receptor & Prognosis:
Estrogen receptor expression is Estrogen receptor expression is proportional to differntiation of tumorproportional to differntiation of tumor
inversly proportional to prognosis and inversly proportional to prognosis and response to tamoxifen (receptor antagonist) response to tamoxifen (receptor antagonist) therapy.therapy.
Demonstrated by Immunoperoxidase Demonstrated by Immunoperoxidase special stain.special stain.
![Page 35: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/35.jpg)
HER2HER2
The HER2 proto-oncogene encodes a cell The HER2 proto-oncogene encodes a cell surface receptor that is overexpressed in surface receptor that is overexpressed in approximately 25%-30% of breast cancers. approximately 25%-30% of breast cancers.
Trastuzumab (Herceptin®) is the first Trastuzumab (Herceptin®) is the first monoclonal antibody that targets the monoclonal antibody that targets the extracelluar domain of the HER2 protein, extracelluar domain of the HER2 protein, and inhibits growth of breast cancer cells and inhibits growth of breast cancer cells that over express this protein. that over express this protein.
![Page 36: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/36.jpg)
Estrogen receptor (ER) in nucleiEstrogen receptor (ER) in nuclei
![Page 37: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/37.jpg)
Immunoperoxidase Positivity Immunoperoxidase Positivity
Neg 1+
2+ 3+
![Page 38: Pathology+of+breast+carcinoma+fsm.ac.fj](https://reader033.vdocument.in/reader033/viewer/2022052910/559b54db1a28ab8b0c8b4636/html5/thumbnails/38.jpg)
Stag
Definition 5-year Surv (%)
7-year Surv (%)
I Tumor 2 cm or less without spread 96 92
II
Tumor 2-5cm with regional lymph node involvement but without distant metastases, OR > 5 cm in diameter without spread
81 71
III
Any size with skin/chest wall fixation, & axillary or internal mammary nodal involvement, without distant metastases
52 39
IV Tumor of any size with or without regional spread but with evidence of distant metastases
18 11